Vanda Pharmaceuticals (VNDA) Return on Capital Employed (2011 - 2026)
Vanda Pharmaceuticals recorded quarterly Return on Capital Employed of 49.24% in Q1 2026, down 30.26% quarter-over-quarter from 37.8% in Q4 2025, and down 3583.0% year-over-year from 1.41% in Q1 2025.
Vanda Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 49.24% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3583.0% year-over-year to 49.24%; the TTM figure through Mar 2026 stood at 49.24% (down 3583.0% YoY), while the FY2025 annual figure was 35.37%, down 2801.0% from the prior year.
- Return on Capital Employed came in at 49.24% for Q1 2026 at Vanda Pharmaceuticals, down from 37.8% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 4.76% in Q1 2022 to a low of 49.24% in Q1 2026.
- A 5-year average of 9.21% and a median of 4.52% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 120 bps in 2023 and plunged 3583 bps in 2026, its largest moves.
- Vanda Pharmaceuticals' Return on Capital Employed stood at 1.18% in 2022, then tumbled by 312 bps to 2.5% in 2023, then tumbled by 195 bps to 7.38% in 2024, then sank by 412 bps to 37.8% in 2025, then sank by 30 bps to 49.24% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 49.24%, 37.8%, and 24.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -49.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.24% |
| Dec 31, 2025 | -37.80% |
| Sep 30, 2025 | -24.46% |
| Jun 30, 2025 | -19.89% |
| Mar 31, 2025 | -13.41% |
| Dec 31, 2024 | -7.38% |
| Sep 30, 2024 | -6.70% |
| Jun 30, 2024 | -5.82% |
| Mar 31, 2024 | -4.52% |
| Dec 31, 2023 | -2.50% |
| Sep 30, 2023 | -0.04% |
| Jun 30, 2023 | 1.74% |
| Mar 31, 2023 | 2.93% |
| Dec 31, 2022 | 1.18% |
| Sep 30, 2022 | 1.59% |
| Jun 30, 2022 | 2.94% |
| Mar 31, 2022 | 4.76% |
| Dec 31, 2021 | 8.23% |
| Sep 30, 2021 | 8.77% |
| Jun 30, 2021 | 8.46% |
| Mar 31, 2021 | 7.91% |
| Dec 31, 2020 | 5.94% |
| Sep 30, 2020 | 4.67% |
| Jun 30, 2020 | 5.52% |
| Mar 31, 2020 | 5.80% |
| Dec 31, 2019 | 5.44% |
| Sep 30, 2019 | 7.63% |
| Jun 30, 2019 | 7.75% |
| Mar 31, 2019 | 6.09% |
| Dec 31, 2018 | 8.08% |
| Sep 30, 2018 | 4.00% |
| Jun 30, 2018 | -0.27% |
| Mar 31, 2018 | -3.46% |
| Dec 31, 2017 | -12.50% |
| Sep 30, 2017 | -11.27% |
| Jun 30, 2017 | -8.42% |
| Mar 31, 2017 | -10.40% |
| Dec 31, 2016 | -11.67% |
| Sep 30, 2016 | -21.23% |
| Jun 30, 2016 | -27.32% |
| Mar 31, 2016 | -27.36% |
| Dec 31, 2015 | -24.28% |
| Sep 30, 2015 | 25.19% |
| Jun 30, 2015 | 30.26% |
| Mar 31, 2015 | 22.59% |
| Dec 31, 2014 | 17.05% |
| Sep 30, 2014 | -131.02% |
| Jun 30, 2014 | -94.06% |
| Mar 31, 2014 | -49.81% |
| Dec 31, 2013 | -18.22% |
| Sep 30, 2013 | -19.05% |
| Jun 30, 2013 | -22.22% |
| Mar 31, 2013 | -24.89% |
| Dec 31, 2012 | -25.57% |
| Sep 30, 2012 | -22.96% |
| Jun 30, 2012 | -19.35% |
| Mar 31, 2012 | -13.13% |
| Dec 31, 2011 | -6.80% |
| Sep 30, 2011 | -2.42% |